Management of Limited‑Patch Alopecia Areata: Evidence‑Based Recommendations

First‑Line Local Therapy

Intralesional corticosteroids are the gold‑standard first‑line treatment for localized alopecia areata in adults, especially in cosmetically sensitive areas. High‑quality evidence supports this recommendation. 3
Triamcinolone acetonide (5–10 mg/mL) injected just beneath the dermis (upper subcutis) is the most commonly used formulation. [3][4]
A single injection of 0.05–0.1 mL typically produces a hair‑growth tuft of about 0.5 cm diameter. 3
Monthly injections yield full regrowth in ≈ 62 % of patients when fewer than five patches each < 3 cm are present; this outcome is superior when disease extent is limited and duration is short. Moderate‑quality evidence (prospective series). [3][4]
The therapeutic effect generally persists for about 9 months after the last injection. 3
The principal drawback is patient discomfort during the procedure. 3

Very potent topical corticosteroids (e.g., clobetasol propionate 0.05 % foam) may be used when intralesional injections are not tolerated, although overall efficacy is more limited. Moderate‑quality evidence. [2][3]
In a randomized controlled trial, 7 of 34 sites treated with clobetasol foam achieved ≥ 50 % regrowth versus 1 of 34 with vehicle after 12 weeks. Level II evidence. [2][3]
Folliculitis is a common adverse effect of potent topical steroids. [2][3]

Diphenylcyclopropenone (DPCP) contact immunotherapy can be considered for stable, extensive disease when other systemic options are unavailable, but it requires administration in specialized centers. [2][3]

Eyebrow hair loss should be treated with intralesional corticosteroids regardless of the extent of scalp disease, given its cosmetic importance. [3][4]

For longstanding, extensive alopecia (totalis/universalis), wigs may be a more realistic option than medical therapy, as full recovery occurs in < 10 % of such cases. [1][2]

Topical minoxidil (1–3 %) shows modest efficacy in extensive disease, with response rates of 32–33 %, but sustained benefit is achieved in < 10 % of patients. Low‑to‑moderate evidence. 4

Disease severity at presentation is the strongest predictor of long‑term outcome. 1
Patients with < 25 % scalp hair loss at onset have a 68 % chance of being disease‑free at long‑term follow‑up. 1
Only 8 % of patients with > 50 % initial hair loss achieve complete remission. 1
Between 14–25 % progress to alopecia totalis/universalis, from which full recovery is uncommon. 1
Nearly all patients experience more than one disease episode over their lifetime. 1

Prolonged PUVA therapy should be avoided because of high cumulative UVA exposure and elevated relapse rates. [3][4]
Reassurance alone is appropriate only for recent‑onset, limited disease (< 1 year duration); patients should be counseled that regrowth is unlikely within 3 months for any individual patch. Level III evidence. 2